(UroToday.com) In a plenary presentation in the Navigating Uncertain Times in Muscle-Invasive and Advanced Bladder Cancer session at the 2021 ASCO GU Cancers Symposium, Dr. Chad Ritch discussed the role of definitive, consolidative therapy following complete response to neoadjuvant chemotherapy.
(UroToday.com) The treatment landscape for first-line therapy among patients with metastatic renal cell carcinoma (mRCC) has changed dramatically over the past 2 years. In 2018, the publication of the CheckMate214 data demonstrated a survival benefit for patients treated with nivolumab and ipilimumab compared with sunitinib in intermediate and poor-risk mRCC, ushering in the immunotherapy era for […]
(UroToday.com) In a plenary presentation in the Navigating Uncertain Times in Muscle-Invasive and Advanced Bladder Cancer session at the 2021 ASCO GU Cancers Symposium, Dr. Valeria Panebianco discussed the optimal approach to radiologic assessment following initial systemic therapy for muscle-invasive bladder cancer.
(UroToday.com) The treatment landscape for first-line therapy among patients with metastatic renal cell carcinoma (mRCC) has changed dramatically over the past 2 years. In 2018, the publication of the CheckMate214 data demonstrated a survival benefit for patients treated with nivolumab and ipilimumab compared with sunitinib in intermediate and poor-risk mRCC, ushering in the immunotherapy era for […]
(UroToday.com) In a plenary presentation in the Navigating Uncertain Times in Muscle-Invasive and Advanced Bladder Cancer session at the 2021 ASCO GU Cancers Symposium, Mr. Richard Bangs provided the patient perspective for those with new diagnoses of muscle-invasive bladder cancer.
(UroToday.com) For patients with muscle-invasive bladder cancer who are eligible for curative-intent treatment, cisplatin-based neoadjuvant chemotherapy (NAC) followed by radical cystectomy (RC) is a standard of care with improved pathologic response and overall survival (OS) compared to RC alone. Consolidation with chemoradiotherapy (CRT) is an alternative to RC. However, many patients are cisplatin-ineligible and thus often […]
(UroToday.com) In the United States, there are significant racial disparities in cancer outcomes. In prostate cancer, observed differences in survival between black and white men were essentially eliminated in the equal access Veterans Affairs’ (VA) system. As with prostate cancer, outcomes in bladder cancer are disproportionately worse for black patients compared to white patients. In a […]
(UroToday.com) For patients with muscle-invasive, localized bladder cancer, neoadjuvant chemotherapy followed by radical cystectomy or trimodal therapy are accepted treatment options. Those who are cisplatin-ineligible/unfit for surgery, or have locally advanced and unresectable disease, have limited treatment options. In a plenary abstract presentation in the Rapid Abstract Session: Urothelial Carcinoma and Rare Tumors session at the […]
Through a ‘seeding grant’, short-term, exploratory research projects can be supported. The results will determine the potential and long-term feasibility of the research. A seeding grant allows young colleagues with ideas for new research initiatives, which may be high-risk projects, to start working on their research project. Last year, the EAU Research Foundation (EAU RF) […]
To evaluate local control and longitudinal endocrine data in monorchid patients treated with testicular-sparing surgery and adjuvant radiotherapy (RT) for seminomatous germ-cell tumors. We searched our database established in 2009 for patients with seminoma who received testis irradiation following partial orchiectomy up to 2018.
